Comment on: clinical value of circulating tumor DNA for patients with epithelial ovarian cancer

Authors

Abstract

The purpose of this letter is to highlight the potential clinical effects and importance of circulating tumor cells and circulating tumor DNA (ctDNA) in oncology patients undergoing PRP (Platelet-Rich Plasma) therapy. ctDNA and circulating tumor cells are considered important biomarkers of disease progression and minimal residual disease in solid tumors. With the increasing use of PRP and exosome-based therapies in cosmetic and regenerative medicine in recent years, the theoretical risk of contamination with tumor material from current or past malignancies, despite these biological products being derived from the patient’s own blood, has been raised. The long-term oncological safety of these applications is not yet clear. On the other hand, the potential role of ctDNA and PRP-derived components in cancer surveillance and personalized oncology treatments is being investigated. Until sufficient long-term evidence is available, it would be appropriate to avoid such bio- logical and cosmetic interventions in patients with a history of cancer or to prefer individualized treatment plans.

Introduction

Letter to the Editor
The purpose of this letter is to highlight the potential clinical implications and importance of circulating tumor cells and DNA in oncology patients undergoing PRP (Platelet-Rich Plasma). The presence of circulating tumor DNA (ctDNA) and tumor cells can be a marker of disease progression and minimal residual disease in solid tumors, similar to hematological malignancies [1].
In recent years, the use of PRP and exosome-based therapies in cosmetic and regenerative medicine has increased. While these products are derived from patients’ own blood and subjected to centrifugation and purification, the theoretical risk of contamination with tumor-derived material from existing or past malignancies remains [2]. Some studies have shown that these biologics may not have adverse effects in the short term; however, the long-term oncological safety of such treat- ments remains uncertain and requires further evaluation [3].
Additionally, many researchers are considering the potential role of circulating tumor DNA and PRP-derived components in cancer treatment monitoring and per- sonalized oncology therapy [4]. However, until sufficient long-term evidence is available, it would be prudent to avoid such biologic/cosmetic interventions or plan individualized treatment for patients with a history of cancer.

Data Availability

The datasets used and/or analyzed during the current study are not publicly available due to patient privacy reasons but are available from the corresponding author on reasonable request.

References

1. Laude É, Azaïs H, Ben Sassi M, Bats AS, Taly V, Laurent-Puig P. Clinical value of circulating tumor DNA for patients with epithelial ovarian cancer. Int J Gynecol Cancer. 2025;35(7):101925. doi:10.1016/j.ijgc.2025.101925.
   Article PubMed Google Scholar
2. Han C, Chen C, Lu N, et al. Platelet-rich plasma inhibits breast cancer proliferation. Clin Med Insights Oncol. 2024;18:11795549241298978. doi:10.1177/11795549241298978.
   Article PubMed Google Scholar
3. Eichler C, Üner J, Thangarajah F, et al. Platelet-rich plasma (PRP) in oncological patients: long-term oncological outcome analysis of the treatment of subcutaneous venous access device scars in 89 breast cancer patients. Arch Gynecol Obstet. 2022;306(4):1171-6. doi:10.1007/s00404-022-06416-4.
   Article PubMed Google Scholar
4. Luzo ACM, Fávaro WJ, Seabra AB, Durán N. What is the potential use of platelet-rich plasma (PRP) in cancer treatment? A mini review. Heliyon. 2020;6(3):e03660. doi:10.1016/j.heliyon.2020.e03660.
   Article PubMed Google Scholar

Scientific Responsibility Statement

The authors declare that they are responsible for the article’s scientific content, including study design, data collection, analysis and interpretation, writing, and some of the main line, or all of the preparation and scientific review of the contents, and approval of the final version of the article.

Animal and Human Rights Statement

All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Funding

None.

Conflict of Interest

The authors declare that there is no conflict of interest.

Additional Information

Publisher’s Note
Bayrakol MP remains neutral with regard to jurisdictional and institutional claims.

Rights and Permissions

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0). To view a copy of the license, visit https://creativecommons.org/licenses/by-nc/4.0/

View full license details →

About This Article